Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Physician Preference of Anti-Diabetic Medications and Complications in Pancreatic Diabetes-An Experience from a Tertiary Care Teaching Hospital


Affiliations
1 Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, Kerala, India
2 Department of Gastroenterology, Amrita Institute of Medical Sciences and Research Centre, Kochi, India
3 Department of Biostatistics, School of Medicine, Amrita Vishwa Vidyapeetham, Kochi, India
4 Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, India
     

   Subscribe/Renew Journal


Aim: There are no guidelines for use of diabetic medications in pancreatic diabetes. Hence we attempted to the benefits of antidiabetic agents in pancreatic diabetes. Materials and methods: a total of 670 chronic pancreatitis patients are selected. Out of that about 126 patients with pancreatic diabetic are selected for the study. The data collected from 2010. Results: In this study mean age was found to be 53.86±12.53. The male patients (73.8%) were more predominant in this study than female patients (26.2%). The complications of chronic pancreatitis among 126 patients, 126 (100) patient had diabetes mellitus (DM), 100 (79) patients had pain. Among 126 patients 52 (41.3%) patients had taken insulin only, 21 (16.7%) patients had taken insulin+ oral combination, 16 (12.7%) patients had taken Biguanides, 13 (10.3%) of patients had taken oral combinations, 13 (10.3%) patients had taken alpha glucosidase inhibitors, 11 (8.7%) patients who are taken sulfonyl ureas. Most of the patients took insulin monotherapy. Conclusion: Insulin was most preferred agent. Metformin was the most commonly preferred oral antidiabetic agent.

Keywords

Chronic Pancreatitis, Type3c DM, Pancreatic Enzymes, Pseudocyst, Malabsorption.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Rajesh G, Veena A B, Menon S, Balakrishnan V. Clinical profile of early onset and late onset idiopathic chronic pancreatitis in india. Indian journal of gastroenterology 2014;33:231-6.
  • Wang W, Guo Y, Liao Z, et al. Occurrence of and risk factors for diabetes mellitus in Chinese patients with chronic pancreatitis. Pancreas 2011;40:206-12.
  • Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology 2000;119:1324-32.
  • Sha, S A Das, A K B Kumar, A G Unnikrishnan, et al. baseline characteristics of the Indian cohort from the improve study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes. Advances in therapy 2009;26:325-35.
  • Meier JJ, Butler PC, Saisho Y et al. beta cell replication is the primary mechanism subserving the postnatal expansion of beta cell mass in humans. Diabetes 2008;57:961–73.
  • Schrader H, Menge BA, Schneider S, et al. Reduced pancreatic volume and beta-cell area in patients with chronic pancreatitis. Gastroenterology 2009;136:513–22.
  • Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013;144:1252-61.
  • Bang UC, Benfield T, Hyldstrup L, Bendtsen F, Jensen JB et al. Mortality, cancer, and comorbidities associated with chronic pancreatitis: A Danish Nationwide Matched-cohort study. Gastroenterology 2014;146:989-994.
  • Pupelis G, Ptasnuka MV, Novikovs V et al. Surgical management of chronic pancreatitis: on the way to a specialised service in Latvia. J Pancreas 2016;17:637-642.
  • Kristiansen L, Gronbaek M, Becker U, Tolstrup JS. Risk of pancreatitis according to alcohol drinking habits: a population based cohort study. Am J Epidemiol 2008;168:932-7
  • L frulloni, A. Gabbrielli, R. Pezzilli et al. Chronic pancreatitis: report from a multicenter Italian survey on 893 patients. Dig Liver Dis 2010;42;156.
  • V balakrishnan, Topical chronic pancreatitis: An update. Medicine update 2008;18:323-329.
  • Singh A and Dwivedi S. Study of adverse drug reactions in patients with diabetes attending a tertiary care hospital in newdelhi, india. Indian J Med Res 2017;145:247-249.
  • Adibe M.O. et al. Outpatient utilization of anti-diabetic drugs in the south eastern nigeria. Int J. Drug Dev & Res 2009;1:27-36.
  • Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharma 2014;5:79-83.
  • Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Exper Opin Drug Saf 2013;12:153-175.

Abstract Views: 188

PDF Views: 0




  • Physician Preference of Anti-Diabetic Medications and Complications in Pancreatic Diabetes-An Experience from a Tertiary Care Teaching Hospital

Abstract Views: 188  |  PDF Views: 0

Authors

K. D. Salima
Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, Kerala, India
Rajesh Gopalakrishna
Department of Gastroenterology, Amrita Institute of Medical Sciences and Research Centre, Kochi, India
Renjitha Bhaskaran
Department of Biostatistics, School of Medicine, Amrita Vishwa Vidyapeetham, Kochi, India
P. R. Roshni
Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi, India

Abstract


Aim: There are no guidelines for use of diabetic medications in pancreatic diabetes. Hence we attempted to the benefits of antidiabetic agents in pancreatic diabetes. Materials and methods: a total of 670 chronic pancreatitis patients are selected. Out of that about 126 patients with pancreatic diabetic are selected for the study. The data collected from 2010. Results: In this study mean age was found to be 53.86±12.53. The male patients (73.8%) were more predominant in this study than female patients (26.2%). The complications of chronic pancreatitis among 126 patients, 126 (100) patient had diabetes mellitus (DM), 100 (79) patients had pain. Among 126 patients 52 (41.3%) patients had taken insulin only, 21 (16.7%) patients had taken insulin+ oral combination, 16 (12.7%) patients had taken Biguanides, 13 (10.3%) of patients had taken oral combinations, 13 (10.3%) patients had taken alpha glucosidase inhibitors, 11 (8.7%) patients who are taken sulfonyl ureas. Most of the patients took insulin monotherapy. Conclusion: Insulin was most preferred agent. Metformin was the most commonly preferred oral antidiabetic agent.

Keywords


Chronic Pancreatitis, Type3c DM, Pancreatic Enzymes, Pseudocyst, Malabsorption.

References